The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma

Oral Diseases

Volumn 17, Issue 5, 2011, Pages 462-468

  Jimi, E ^a   Furuta, H ^a   Matsuo, K ^a   Tominaga, K ^a   Takahashi, T ^a   Nakanishi, O ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Bone invasion; IL 6; Oral squamous cell carcinomas; RANKL

Indexed keywords

GROWTH FACTOR; INTERLEUKIN 11; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BONE MATRIX; CANCER INVASION; CELL FUNCTION; CELL GROWTH; HISTOPATHOLOGY; HUMAN; MANDIBLE; MANDIBLE CANCER; MICROENVIRONMENT; MOLECULAR DYNAMICS; MOUTH CARCINOMA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR CELL;

BONE RESORPTION; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; HUMANS; MANDIBLE; MANDIBULAR NEOPLASMS; MOLECULAR BIOLOGY; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; OSTEOCLASTS;

EID: 79957939457     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01781.x     Document Type: Review

References (50)

1. Bendre M, Gaddy D, Nicholas RW, Suva LJ (2003). Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res 415(Suppl.): S39-45.
2. Body JJ, Facon T, Coleman RE et al (2006). A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228.
3. Boyle WJ, Simonet WS, Lacey DL (2003). Osteoclast differentiation and activation. Nature 423: 337-342.
4. Brown JM, Corey E, Lee ZD et al (2001). Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57: 611-616.
5. Burtis WJ, Wu T, Bunch C et al (1987). Identification of a novel 17, 000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 262: 7151-7156.
6. Carter RL, Tsao SW, Burman JF, Pittam MR, Clifford P, Shaw HJ (1983). Patterns and mechanisms of bone invasion by squamous carcinomas of the head and neck. Am J Surg 146: 451-455.
7. Chen Z, Malhotra PS, Thomas GR et al (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379.
8. Choi S, Myers JN (2008). Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87: 14-32.
9. Duffy SA, Taylor JM, Terrell JE et al (2008). Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750-757.
10. Farrugia AN, Atkins GJ, To LB et al (2003). Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445.
11. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533.
12. Goda T, Shimo T, Yoshihama Y et al (2010). Bone destruction by invading oral squamous carcinoma cells mediated by the transforming growth factor-β signalling pathway. Anticancer Res 30: 2615-2623.
13. Guise TA (2009). Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 23: 2117-2123.
14. Guise TA, Mundy GR (1998). Cancer and bone. Endocr Rev 19: 18-54.
15. Ishikuro M, Sakamoto K, Kayamori K et al (2008). Significance of the fibrous stroma in bone invasion by human gingival squamous cell carcinomas. Bone 43: 621-627.
16. Ito M, Izumi N, Cheng J et al (2003). Jaw bone remodeling at the invasion front of gingival squamous cell carcinomas. J Oral Pathol Med 32: 10-17.
17. Jablońska E, Piotrowski L, Grabowska Z (1997). Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity Cancer. Pathol Oncol Res 3: 126-129.
18. Jimi E, Shuto T, Koga T (1995). Macrophage colony-stimulating factor and interleukin-1 α maintain the survival of osteoclast-like cells. Endocrinology 136: 808-811.
19. Jimi E, Nakamura I, Amano H et al (1996). Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137: 2187-2190.
20. Jimi E, Akiyama S, Tsurukai T et al (1999). Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163: 434-442.
21. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M (1997). Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 70: 120-127.
22. Kayamori K, Sakamoto K, Nakashima T et al (2010). Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 176: 968-980.
23. McGregor AD, MacDonald DG (1988). Routes of entry of squamous cell carcinoma to the mandible. Head Neck 10: 294-301.
24. McGregor AD, MacDonald DG (1993). Patterns of spread of squamous cell carcinoma to the ramus of the mandible. Head Neck 15: 440-444.
25. Muir C, Weiland L (1995). Upper aerodigestive tract cancers. Cancer 75: 147-153.
26. Müller H, Slootweg PJ (1990). Mandibular invasion by oral squamous cell carcinoma. Clinical aspects. J Craniomaxillofac Surg 18: 80-84.
27. Nagai N, Kyakumoto S, Sato N (2000). Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 269: 532-536.
28. Nakashima T, Wada T, Penninger JM (2003). RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15: 280-287.
29. 3 or parathyroid hormone. J Biol Chem 274: 19301-19308.
30. Ohshiba T, Miyaura C, Inada M, Ito A (2003). Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer 88: 1318-1326.
31. Okamoto M, Hiura K, Ohe G et al (2000). Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 89: 1966-1975.
32. Otoh EC, Johnson NM, Olasoji HO, Danfillo IS, Adeleke OA (2005). Intra-oral carcinomas in Maiduguri, north-eastern Nigeria. Oral Dis 11: 379-385.
33. Papadimitrakopoulou VA, Brown EN, Liu DD et al (2006). The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239: 136-143.
34. Partridge M, Kiguwa S, Luqmani Y, Langdon JD (1996). Expression of bFGF, KGF and FGF receptors on normal oral mucosa and SCC. Eur J Cancer B Oral Oncol 32B: 76-82.
35. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003). RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098.
36. Shah J, Lydiatt WM (1999) Buccal mucosa, alveolus, retromolar trigone, floor of mouth, hard palate, and tongue tumors. In: Thawley SE, ed. Comprehensive Management of Head and Neck Tumors. 2nd edn. WB Saunders: Philadelphia, pp. 686-693.
37. Shibahara T, Nomura T, Cui NH, Noma H (2005). A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. Int J Oral Maxillofac Surg 34: 789-93.
38. Slootweg PJ, Muller H (1989). Mandibular invasion by oral squamous cell carcinoma. J Craniomaxillofac Surg 17: 69-74.
39. Sokolosky M Jr, Bouquot JE, Graves RW (1986). Esophageal carcinoma metastatic to the oral cavity. J Oral Maxillofac Surg 44: 825-827.
40. Stephenson J (2000). Researchers buoyed by promise of targeted leukemia therapy. JAMA 283: 317-321.
41. Stoeckli SJ, Pfaltz M, Steinert H, Schmid S (2002). Histopathological features of occult metastasis detected by sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma. Laryngoscope 112: 111-115.
42. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357.
43. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K (2005). Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 116: 253-262.
44. Tada T, Shin M, Fukushima H et al (2009). Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett 274: 126-131.
45. Thomas RJ, Guise TA, Yin JJ et al (1999). Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458.
46. Totsuka Y, Usui Y, Tei K et al (1991a). Results of surgical treatment for squamous carcinoma of the lower alveolus: segmental vs. marginal resection. Head Neck 13: 114-20.
47. Totsuka Y, Usui Y, Tei K et al (1991b). Mandibular involvement by squamous cell carcinoma of the lower alveolus: analysis and comparative study of histologic and radiologic features. Head Neck 13: 40-50.
48. Uchida Y (1998). Statistical and epidemic studies oral cancer diagnosed and treated by oral surgeons in Japan. Jpn J Oral Biol 7: 16-26.
49. Wong RJ, Keel SB, Glynn RJ, Varvares MA (2000). Histological pattern of mandibular invasion by oral squamous cell carcinoma. Laryngoscope 110: 65-72.
50. Yaccoby S, Wezeman MJ, Henderson A et al (2004). Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64: 2016-2023.